Press Release
ctDNA in DLBCL: A Blueprint for Better Clinical Trials?
Current clinical characteristics and demographics are not sufficient to capture aggressive disease in clinical trials of newly diagnosed DLBCL. Novel tools, such as measurement of tumor burden via ctDNA, are needed. By : Dr. Matthew Maurer.
Related Topics
You May Also Like
Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
Press Release
Introducing OncologyVoiceNetwork.com
Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
Podcast